open access
MSCs and CAFs interactions in the prostate and bladder cancer microenvironment as the potential cause of tumour progression
, 1, 1, 1
Affiliations- Chair of Urology and Andrology, Department of Tissue Engineering, The Ludwik Rydygier Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
open access
Abstract
The tumour microenvironment (TME) is the broadly understood environment around the tumour. Cancer-associated fibroblasts (CAFs), Mesenchymal Stromal Cells (MSCs), and molecules synthesized by them are part of it. Both CAFs and MSCs can promote tumour progression by induction of an immunosuppressive, pro-inflammatory environment. Through indirect and direct cell-to-cell interactions they also have a pro-proliferative, pro-angiogenic, and pro-invasive effect on cancer cells. They can lead to aggressive cancer formation. At this stage, it is important to conduct research to modulate TME towards inhibition of cancer progression and preventing resistance to already introduced drugs. Moreover, it is extremely important to study these interactions in light of using MSCs in a drug-delivery strategy.
Abstract
The tumour microenvironment (TME) is the broadly understood environment around the tumour. Cancer-associated fibroblasts (CAFs), Mesenchymal Stromal Cells (MSCs), and molecules synthesized by them are part of it. Both CAFs and MSCs can promote tumour progression by induction of an immunosuppressive, pro-inflammatory environment. Through indirect and direct cell-to-cell interactions they also have a pro-proliferative, pro-angiogenic, and pro-invasive effect on cancer cells. They can lead to aggressive cancer formation. At this stage, it is important to conduct research to modulate TME towards inhibition of cancer progression and preventing resistance to already introduced drugs. Moreover, it is extremely important to study these interactions in light of using MSCs in a drug-delivery strategy.
Keywords
tumour microenvironment, cancer-associated fibroblasts, mesenchymal stromal cells
About this articleTitle
MSCs and CAFs interactions in the prostate and bladder cancer microenvironment as the potential cause of tumour progression
Journal
Issue
Article type
Review article
Pages
68-75
Published online
2023-03-09
Page views
2170
Article views/downloads
303
DOI
Bibliographic record
Medical Research Journal 2023;8(1):68-75.
Keywords
tumour microenvironment
cancer-associated fibroblasts
mesenchymal stromal cells
Authors
Karolina Balik
Łukasz Kaźmierski
Małgorzata Maj
Anna Bajek
References (50)- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–249.
- Al-toub M, Almusa A, Almajed M, et al. Pleiotropic effects of cancer cells' secreted factors on human stromal (mesenchymal) stem cells. Stem Cell Res Ther. 2013; 4(5): 114.
- Xiong Y, Wang Y, Tiruthani K. Tumor immune microenvironment and nano-immunotherapeutics in colorectal cancer. Nanomedicine. 2019; 21: 102034.
- Yang YHK. Aging of mesenchymal stem cells: Implication in regenerative medicine. Regen Ther. 2018; 9: 120–122.
- Lynch MD, Watt FM. Fibroblast heterogeneity: implications for human disease. J Clin Invest. 2018; 128(1): 26–35.
- Kusuma GD, Carthew J, Lim R, et al. Effect of the Microenvironment on Mesenchymal Stem Cell Paracrine Signaling: Opportunities to Engineer the Therapeutic Effect. Stem Cells Dev. 2017; 26(9): 617–631.
- Soundararajan M, Kannan S. Fibroblasts and mesenchymal stem cells: Two sides of the same coin? J Cell Physiol. 2018; 233(12): 9099–9109.
- Lazennec G, Lam PY. Recent discoveries concerning the tumor - mesenchymal stem cell interactions. Biochim Biophys Acta. 2016; 1866(2): 290–299.
- Kurniawati I, Liu MC, Hsieh CL, et al. Targeting Castration-Resistant Prostate Cancer Using Mesenchymal Stem Cell Exosomes for Therapeutic MicroRNA-let-7c Delivery. Front Biosci (Landmark Ed). 2022; 27(9): 256.
- Zhu Y, Sun Z, Han Q, et al. Human mesenchymal stem cells inhibit cancer cell proliferation by secreting DKK-1. Leukemia. 2009; 23(5): 925–933.
- Mortensen MM, Høyer S, Lynnerup AS, et al. Expression profiling of prostate cancer tissue delineates genes associated with recurrence after prostatectomy. Sci Rep. 2015; 5: 16018.
- Hughes RM, Simons BW, Khan H, et al. Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic Progression. Cancer Res. 2019; 79(14): 3636–3650.
- Hurley PJ, Sundi D, Shinder B, et al. Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer. Clin Cancer Res. 2016; 22(2): 448–458.
- Awata T, Yamada S, Tsushima K, et al. PLAP-1/Asporin Positively Regulates FGF-2 Activity. J Dent Res. 2015; 94(10): 1417–1424.
- Bhuniya A, Sarkar A, Guha A, et al. Tumor activated platelets induce vascular mimicry in mesenchymal stem cells and aid metastasi. Cytokine. 2022; 158: 155998.
- Luo F, Su Y, Zhang Z, et al. Bone marrow mesenchymal stem cells promote the progression of prostate cancer through the SDF-1/CXCR4 axis in vivo and vitro. Clin Transl Oncol. 2022; 24(5): 892–901.
- Zimmerlin L, Park TS, Zambidis ET, et al. Mesenchymal stem cell secretome and regenerative therapy after cancer. Biochimie. 2013; 95(12): 2235–2245.
- Halim NS, Aizat WM, Yahaya BH. The effect of mesenchymal stem cell-secreted factors on airway epithelial repair. Regen Med. 2019; 14(1): 15–31.
- Pessina A, Bonomi A, Coccè V, et al. Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy. PLoS One. 2011; 6(12): e28321.
- Li M, Zhang F, Chen K, et al. Nanoparticles and mesenchymal stem cells: a win-win alliance for anticancer drug delivery. RSC Advances. 2016; 6(43): 36910–36922.
- Roger M, Clavreul A, Venier-Julienne MC, et al. Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors. Biomaterials. 2010; 31(32): 8393–8401.
- Levy O, Brennen WN, Han E, et al. A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer. Biomaterials. 2016; 91: 140–150.
- Greco KA, Franzen CA, Foreman KE, et al. PLK-1 Silencing in Bladder Cancer by siRNA Delivered With Exosomes. Urology. 2016; 91: 241.e1–241.e7.
- Denu RA, Nemcek S, Bloom DD, et al. Fibroblasts and Mesenchymal Stromal/Stem Cells Are Phenotypically Indistinguishable. Acta Haematol. 2016; 136(2): 85–97.
- Brohem CA, de Carvalho CM, Radoski CL, et al. Comparison between fibroblasts and mesenchymal stem cells derived from dermal and adipose tissue. Int J Cosmet Sci. 2013; 35(5): 448–457.
- Blasi A, Martino C, Balducci L, et al. Dermal fibroblasts display similar phenotypic and differentiation capacity to fat-derived mesenchymal stem cells, but differ in anti-inflammatory and angiogenic potential. Vasc Cell. 2011; 3(1): 5.
- Wang M, Zhao J, Zhang L, et al. Role of tumor microenvironment in tumorigenesis. J Cancer. 2017; 8(5): 761–773.
- Ringuette Goulet C, Bernard G, Tremblay S, et al. Exosomes Induce Fibroblast Differentiation into Cancer-Associated Fibroblasts through TGFβ Signaling. Mol Cancer Res. 2018; 16(7): 1196–1204.
- Shangguan L, Ti X, Krause U, et al. Inhibition of TGF-β/Smad signaling by BAMBI blocks differentiation of human mesenchymal stem cells to carcinoma-associated fibroblasts and abolishes their protumor effects. Stem Cells. 2012; 30(12): 2810–2819.
- Tanaka K, Miyata H, Sugimura K, et al. miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts. Carcinogenesis. 2015; 36(8): 894–903.
- De Vincenzo A, Belli S, Franco P, et al. Paracrine recruitment and activation of fibroblasts by c-Myc expressing breast epithelial cells through the IGFs/IGF-1R axis. Int J Cancer. 2019; 145(10): 2827–2839.
- Li Z, Zhou J, Zhang J, et al. Cancer-associated fibroblasts promote PD-L1 expression in mice cancer cells via secreting CXCL5. Int J Cancer. 2019; 145(7): 1946–1957.
- Monteran L, Erez N. The Dark Side of Fibroblasts: Cancer-Associated Fibroblasts as Mediators of Immunosuppression in the Tumor Microenvironment. Front Immunol. 2019; 10: 1835.
- Ellem SJ, Taylor RA, Furic L, et al. A pro-tumourigenic loop at the human prostate tumour interface orchestrated by oestrogen, CXCL12 and mast cell recruitment. J Pathol. 2014; 234(1): 86–98.
- Barnas JL, Simpson-Abelson MR, Yokota SJ, et al. T cells and stromal fibroblasts in human tumor microenvironments represent potential therapeutic targets. Cancer Microenviron. 2010; 3(1): 29–47.
- Wu CT, Chen MF, Chen WC, et al. The role of IL-6 in the radiation response of prostate cancer. Radiat Oncol. 2013; 8: 159.
- Ma F, Chen D, Chen F, et al. Human Umbilical Cord Mesenchymal Stem Cells Promote Breast Cancer Metastasis by Interleukin-8- and Interleukin-6-Dependent Induction of CD44(+)/CD24(-) Cells. Cell Transplant. 2015; 24(12): 2585–2599.
- Erdogan B, Webb DJ. Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis. Biochem Soc Trans. 2017; 45(1): 229–236.
- Eble JA, Niland S. The extracellular matrix in tumor progression and metastasis. Clin Exp Metastasis. 2019; 36(3): 171–198.
- Wang L, Zhang F, Cui JY, et al. CAFs enhance paclitaxel resistance by inducing EMT through the IL‑6/JAK2/STAT3 pathway. Oncol Rep. 2018; 39(5): 2081–2090.
- Shintani Y, Fujiwara A, Kimura T, et al. IL-6 Secreted from Cancer-Associated Fibroblasts Mediates Chemoresistance in NSCLC by Increasing Epithelial-Mesenchymal Transition Signaling. J Thorac Oncol. 2016; 11(9): 1482–1492.
- Wang L, Chen W, Li X, et al. WITHDRAWN: Stromal Cell-Derived Factor 1 Secreted by Cancer- Associated Fibroblasts Promotes lncRNA Xist through CXCR4 and Facilitates Invasion and Metastasis of Non-Small Cell Lung Cancer. Curr Cancer Drug Targets. 2022 [Epub ahead of print].
- Teng F, Tian WY, Wang YM, et al. Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis. J Hematol Oncol. 2016; 9: 8.
- Wang Z, Ma Q, Liu Q, et al. Blockade of SDF-1/CXCR4 signalling inhibits pancreatic cancer progression in vitro via inactivation of canonical Wnt pathway. Br J Cancer. 2008; 99(10): 1695–1703.
- Huang W, Zhang L, Yang Mi, et al. Cancer-associated fibroblasts promote the survival of irradiated nasopharyngeal carcinoma cells via the NF-κB pathway. Journal of Experimental & Clinical Cancer Research. 2021; 40(1).
- Steer A, Cordes N, Jendrossek V, et al. Impact of Cancer-Associated Fibroblast on the Radiation-Response of Solid Xenograft Tumors. Front Mol Biosci. 2019; 6: 70.
- Bruzzese F, Hägglöf C, Leone A, et al. Local and systemic protumorigenic effects of cancer-associated fibroblast-derived GDF15. Cancer Res. 2014; 74(13): 3408–3417.
- Senapati S, Rachagani S, Chaudhary K, et al. Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK-RhoA signaling pathway. Oncogene. 2010; 29(9): 1293–1302.
- Saranchova I, Han J, Huang H, et al. Discovery of a Metastatic Immune Escape Mechanism Initiated by the Loss of Expression of the Tumour Biomarker Interleukin-33. Sci Rep. 2016; 6: 30555.
- Miyake M, Hori S, Morizawa Y, et al. CXCL1-Mediated Interaction of Cancer Cells with Tumor-Associated Macrophages and Cancer-Associated Fibroblasts Promotes Tumor Progression in Human Bladder Cancer. Neoplasia. 2016; 18(10): 636–646.